MedTrace Logo

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

NCT04645589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2025-12-09

No results posted yet for this study

Summary

This is an open-label, prospective, single-arm, observational study in patients with Lupus nephritis (LN) who newly (i.e.,for the first time) received treatment of Enteric-coated Mycophenolate Sodium (EC-MPS).

Conditions

Interventions

DRUG

Myfortic

There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2025-06-13
Completion
2025-06-13

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645589 on ClinicalTrials.gov